Dossier assessment
Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to <18 years of age) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to <18 years of age) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to <18 years of age) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Chronic hepatitis C in adolescents aged 12 to < 18 years
Result of dossier assessment:
- Genotype 1, 4, 5 or 6: added benefit not proven.
- Genotype 2 or 3: added benefit not proven.
Project details
- Project no.
- A21-136
- Commission
- Commission awarded on 15.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.